Regular Article
Comparative Developmental Toxicity and Metabolism of Nitrazepam in Rats and Mice

https://doi.org/10.1006/taap.1993.1150Get rights and content

Abstract

This study was designed to evaluate the developmental toxicity of nitrazepam (NZ) in Sprague-Dawley rats and ICR mice and to determine the metabolic factors which modulate susceptibility to the developmental effects of NZ. Rats were treated orally with a single dose of NZ at 300 mg/kg on Day 12 of gestation. Mice received one dose of 300 mg/kg NZ via gavage between Days 9 and 14 of gestation. NZ administration resulted in a significant incidence of malformations in rats, while no evidence of teratogenic action was observed in mice. Pronounced species differences in the metabolism of NZ were observed. In rats, 7-acetylaminonitrazepam (AANZ) was detected as the major metabolite in plasma and embryos, whereas in mice, only small amounts of this product were found. The rate of N-acetylation of 7-aminonitrazepam (ANZ) to AANZ was 8.5-fold greater in rat liver cytosol than that in mouse liver cytosol. In contrast, the rate of deacetylation of AANZ to ANZ was 9-fold greater in mouse liver microsomes than that in rat liver microsomes. The developmental effects of authentic metabolites of NZ were studied in the two species. A single oral administration of 300 mg/kg ANZ to pregnant animals produced a significant incidence of malformations in rats, but not in mice. On the other hand, AANZ was teratogenic in both species. These results suggest that the difference in the susceptibility to NZ-induced teratogenicity between rats and mice may be related to differences in the levels of N-acetyltransferase and deacetylase, and that AANZ may be involved in the teratogenic mechanism.

References (0)

Cited by (29)

  • Xenobiotics and drug-metabolizing enzymes: Challenges and strategies

    2022, Biochemistry of Drug Metabolizing Enzymes: Trends and Challenges
  • Modulation of human microbiome and drug metabolism

    2022, Biochemistry of Drug Metabolizing Enzymes: Trends and Challenges
  • Mechanisms of gastrointestinal microflora on drug metabolism in clinical practice

    2019, Saudi Pharmaceutical Journal
    Citation Excerpt :

    The involvement of gut microbiota in the metabolism of nitrazepam, a hypnotic, sedative, anticonvulsant and anxiolytic drug, into its teratogenicity was demonstrated in experiments with rats (Takeno and Sakai, 1991). Nitrazepam is transformed to 7-aminonitrazepam by nitroreductase from intestinal microbiota, followed by acetylation to 7-acetylaminonitrazepam in the liver (Takeno et al., 1993). Although reductive metabolism in rat liver is less potent than in gastrointestinal tract (Rafii, 1997), two metabolites are both teratogenic.

  • Identification of enzymes responsible for nitrazepam metabolism and toxicity in human

    2017, Biochemical Pharmacology
    Citation Excerpt :

    In humans, NZP is primarily metabolized to 7-amino nitrazepam (ANZP) by nitro-reductase(s) and subsequently to 7-acetylamino nitrazepam (AANZP) by N-acetyltransferase(s) (Fig. 1) [8]. In rodents, AANZP is hydrolyzed to ANZP in the liver, but it has not been determined whether this reaction occurs in humans [7]. Within 24 hours of an oral administration of 10 mg NZP in humans, urinary excretion of ANZP and AANZP represented 4.1% and 12.5% of the initial dose, respectively, [9].

View all citing articles on Scopus
View full text